| Business Summary | | Ribozyme
Pharmaceuticals,
Inc.
is
developing
a
new
class
of
drugs
based
on
ribozymes.
Ribozymes
are
engineered
molecules
that
have
the
ability
to
cleave
RNA,
including
mRNA
and
viral
RNA,
and
thereby
selectively
inhibit
protein
production
and
viral
replication.
The
Company
expects
to
initiate
five
Phase
II
clinical
trials
in
2001
for
its
lead
product
candidate,
Angiozyme,
for
the
treatment
of
solid
tumor
cancers
with
which
it
is
in
collaboration
with
Chiron.
The
Company
also
expects
to
initiate
a
Phase
II
clinical
trial
in
2001
for
Heptazyme,
its
product
candidate
for
the
treatment
of
chronic
Hepatitis
C.
In
addition,
the
Company
recently
formed
a
joint
venture
with
Elan
Corporation
plc
to
develop
Herzyme,
a
treatment
for
breast
and
other
cancers. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Ribozyme
Pharmaceuticals
is
developing
a
new
class
of
drugs
based
on
ribozymes,
engineered
molecules
that
have
the
ability
to
cleave
RNA,
including
mRNA,
and
thereby
selectively
inhibit
protein
production.
For
the
six
months
ended
6/30/01,
total
revenues
fell
42%
to
$4.5
million.
Net
loss
applicable
to
Common
totaled
$22.6
million,
up
from
$5.6
million.
Results
reflect
the
termination
of
the
Eli
Lilly
collaboration
and
an
increase
in
contract
R&D
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| David Morgenthaler, 81 Chairman
of Directors | -- | -- | Howard Robin, 48 Pres,
CEO, Chief Operating Officer, Director | -- | -- | Marvin Tancer CFO,
VP-Operations | -- | -- | Lawrence Bullock, 44 VP
of Fin. and Admin. | $227K | -- | Lawrence Blatt, Ph. D., 39 VP
of Research | 225K | $1.1M | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|